

Novel lipoplexes for efficient microRNA delivery to human cardiac fibroblasts

Original

Novel lipoplexes for efficient microRNA delivery to human cardiac fibroblasts / Nicoletti, Letizia; Tarricone, Giulia; Paoletti, Camilla; Divieto, Carla; Andreana, Ilaria; Stella, Barbara; Arpicco, Silvia; Mattu, Clara; Chiono, Valeria. - ELETTRONICO. - (2020). (Intervento presentato al convegno Vancouver Nanomedicine Day tenutosi a Virtual nel 17 Sept. 2020).

Availability:

This version is available at: 11583/2846180 since: 2020-09-21T09:35:56Z

Publisher:

University British Columbia Vancouver

Published


DOI:

Terms of use:

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)



Novel lipoplexes for efficient microRNA delivery to human cardiac fibroblasts

Letizia Nicoletti¹, Giulia Tarricone¹, Camilla Paoletti¹, Carla Divieto², Ilaria Andreana³, Barbara Stella³, Silvia Arpicco³, Clara Mattu¹, Valeria Chiono^{1*}

¹Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy, valeria.chiono@polito.it;

²Division of Metrology for Quality of Life, Istituto Nazionale di Ricerca Metrologica, Turin, Italy;

³Department of Drug Science and Technology, University of Turin, Turin, Italy

Myocardial infarction causes the irreversible loss of cardiomyocytes and the formation of a dysfunctional fibrotic scar. Among advanced therapies for myocardial regeneration, *in situ* release of specific microRNAs (miRNAs) is under evaluation to promote cardiomyocyte proliferation or transdifferentiation of cardiac fibroblasts (CFs) into cardiomyocytes [1, 2].

In this work, new miRNAs-loaded lipoplexes were designed for efficient encapsulation and delivery of miRNAs to human CFs, aimed at triggering their direct reprogramming into cardiomyocytes. Lipoplexes containing negmiR or miR-1 were prepared at different N:P ratios, showing 99% encapsulation efficiency, hydrodynamic diameter ranging from 372 nm to 876 nm and average zeta potential ranging from +40 mV to -26 mV with decreasing N:P ratio from 3.0 to 0.35. Based on stability experiments in different media at different temperatures (4°C and 37°C), lipoplexes with N:P 3 were selected for *in vitro* tests with human CFs, showing more efficient miR-1 release to CFs, as compared to a commercial agent. Direct reprogramming experiments are in progress using miRcombo (miR-1, 133, 208, 499) to validate the newly developed lipoplexes as efficient vectors for direct cardiac reprogramming compared to a commercial agent [2].

This project is supported from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 772168).

1. Lee S W L, Paoletti C, Campisi M, Osakie T, Adrianid G, Kamm RD, Mattu C, Chiono V (2019). **MicroRNA delivery through nanoparticles**. J Control Release 313, 80-95
2. Paoletti C, Divieto C, Tarricone G., Di Meglio F, Nurzynska D, Chiono V (2020). **MicroRNA-Mediated Direct Reprogramming of Human Adult Fibroblasts Toward Cardiac Phenotype**. Front Bioeng Biotechnol. 8, 529.